Drug shortages in the U.S. have been an ongoing concern over the last couple of years, and have come to a head in recent months. Two cancer drugs in particular, Doxil (doxorubicin hydrochloride liposome injection) and the life-saving methotrexate are in short supply, but the FDA has made plans they say should swiftly reverse the situation.
Shortages of the medications worsened when a major manufacturing plant, Ben Venue Laboratories, shut down production due to safety concerns. To make up for the deficit, the FDA has decided to allow imports of a Doxil substitute, called Lipodox (doxorubicin hydrochloride liposome injection), which will apparently meet demand over the coming weeks. To address the methotrexate shortage, the Agency has approved another manufacturer to import a preservative-free generic version of the cancer drug to boost supplies.
Read the full story: http://hcp.lv/IJyGtG
Source: The Atlantic
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More